Background Long-term administration of oral β 2 -adrenergic receptor agonists (β 2 -AG) in patients with bronchial asthma (BA) causes disastrous events such as sudden death and heart attack. However, long-term effects of β 2 -AG on cardiac function have not been previously quantified.
Methods Seventy-four patients with BA with regular long-term use of oral β 2 -AG (group A) and 69 patients with BA without β 2 -AG (group B) were examined in medical records of outpatient clinics from 1985 to 1999. In the prospective study, echocardiography was performed in 48 consecutive patients from January to April 1999. There were 26 patients with regular oral use of β 2 -AG (group a) and 22 patients without β 2 -AG (group b). Twenty-one age-matched normal volunteers without heart or pulmonary diseases were used as control subjects (group c). Oral β 2 -AG was withdrawn from remedies in 11 patients of group a, and echocardiographic studies were repeated 2 weeks after its cessation.
Results Events related to heart failure were more frequently seen in group A than in group B (14% vs 1%, P < .01). The echocardiographic study showed that indexes of left ventricular diastolic but not systolic function were significantly deteriorated in group a, along with a markedly reduced level of plasma norepinephrine concentration (P < .05 vs groups b and c). When heart rate was adjusted to 90 beats/min during isoproterenol infusion, left ventricular diastolic function remained deteriorated in group a (P < .05 vs groups b and c). In 11 patients of group a, the cessation of β 2 -AG for 2 weeks resulted in an improvement of left ventricular diastolic function and in an increase of plasma norepinephrine level (P < .01).
Conclusions Long-term use of oral β 2 -AG impaired left ventricular diastolic function in patients with BA, and the cessation of β 2 -AG reversed diastolic pump performance to the normal level. (Am Heart J 2001;142:e11.) years) (group A: mean age, 56 ± 2 years) and the other 69 were without oral β 2 -AG (group B: 51 ± 2 years). Regular use of inhaled steroids was found in 51 cases (69%) in group A and 45 (65%) in group B (not significant between groups). Oral preparations of β 2 -AGs were intermediate-acting or long-acting types; procaterol hydrochloride was given to 30 cases, clenbuterol hydrochloride to 17 cases, mabuterol hydrochloride to 14 cases, and tulobuterol hydrochloride to 13 cases. In examining clinical records, cardiovascular morbidity (such as history of angina, congestive heart failure, hypertension, and ventricular premature beats) was counted. Spirometric examinations were performed before the daily intake of β 2 -AG or corticosteroids as controller treatments.
In study 2, 48 consecutive patients with bronchial asthma from January to April 1999 were enrolled in the echocardiographic and clinical observation studies. Informed consent was obtained from patients. The study protocol was approved by the local ethics committee of the Yamagata University School of Medicine. Twenty-six patients from group A (group a) and 22 patients from group B (group b) were included and matched for age and sex. Patients with diabetes mellitus, atrial fibrillation, cardiovascular diseases, neurologic disorders, or heart failure were excluded. Oral preparations of β 2 -AGs in group a were as follows: procaterol hydrochloride in 16 cases, clenbuterol hydrochloride in 4 cases, mabuterol hydrochloride in 3 cases, and tulobuterol hydrochloride in 3 cases. For controller treatments, inhaled corticosteroids were regularly prescribed to 18 (69%) and 15 cases (68%) in groups a and b, respectively. Twenty-one age-and sex-matched healthy volunteers were used as control subjects (group c). All subjects accepted to receive further echocardiographic examinations along with spirometric tests and measurements of plasma norepinephrine concentrations. Subgroup analysis among different β 2 -AGs was not performed because of the small numbers involved.
In study 3, 11 of 26 patients in study 2 agreed to participate in the withdrawal study. Two weeks after the cessation of β 2 -AG, the echocardiographic studies were repeated.
Laboratory examinations
All studies were performed in the morning, with the subjects in a fasting state. Measurements of plasma norepinephrine concentration and spirometric tests were performed before the echocardiographic study. The plasma norepinephrine levels were measured by automated microparticle immunoassay and were calibrated according to the World Health Organization International Reference Standard. Forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) were measured by a dry-wedge bellows spirometer (CHESTAC-25, Chest Co, Tokyo, Japan) and were determined as the mean of 3 repetitive values.
Echocardiographic studies
Echocardiograms were recorded with the use of an Acuson 128XP instrument equipped with a multifrequency transducer (Acuson, Mountain View, Calif). Conventional Doppler, Mmode, and 2D studies were performed with the use of standard views and techniques. Left ventricular percent fractional shortening (%FS) was calculated by using the left ventricular end-diastolic (LVDd) and end-systolic (LVDs) dimensions: %FS = [(LVDd -LVDs)/LVDd] × 100.
Transmitral and transtricuspid inflow velocities were recorded on the apical 4-chamber view for assessing left and right ventricular diastolic functions, respectively. With the guidance of a real-time 2D color Doppler flow image, the Doppler sample volume was placed at the tip of the mitral and tricuspid annuli and the position was then adjusted to direct the ultrasound beam parallel to ventricular inflow. The ratio of peak early filling velocity to peak late filling velocity (E/A) and the deceleration time of the early diastolic filling (DT) were measured. 16 As an index of pulmonary artery pressure, we measured the ratio of acceleration time to ejection time (AcT/ET) in right ventricular outflow velocity curves. 17 During intravenous isoproterenol infusion, echocardiographic parameters were measured at the matched heart rate of 90 beats/min. All measurements were taken as the mean of 5 consecutive cardiac cycles on a strip chart at a paper speed of 100 mm/s.
Statistical analysis
Continuous data were expressed as mean ± standard error of the mean (SEM). A Student t test for unpaired data was used to assess statistical significance of the difference between patients with regular use of oral β 2 -AG and without oral β 2 -AG. A paired t test was used to compare the difference before and 2 weeks after cessation of oral β 2 -AG. Analysis of variance followed by Scheffé test was used to assess the statistical difference among normal subjects and patients with bronchial asthma with and without regular use of oral β 2 -AG. Values of P < .05 were considered significant.
Results β 2 -AG and heart failure
On the basis of clinical records, there were no significant differences in age, histories of angina, ventricular arrhythmia, hypertension, or other remedies for asthma (theophylline, corticosteroids, and inhaled β 2 -agonists) between patients with and those without oral β 2 -AG (Table I) . Ten patients with congestive heart failure and 1 with respiratory failure in group A and 3 with respiratory failure and 1 with respiratory infection in group B were admitted to our hospital. Twelve patients died. The cause of death was congestive heart failure in 2 cases, acute myocardial infarction in 2 cases, respiratory failure in 2 cases, sudden death in 1 case, and death from a traffic accident in 1 case: in group B, there were 2 cases of respiratory failure, 1 death from cancer, and 1 death from a traffic accident. The incidence of nonfatal heart failure associated with administration of oral nitrates was more frequently observed in group A than in group B.
Echocardiographic evaluation
There were no significant differences in age, sex, numbers of other asthmatic drugs, and right ventricular function in echocardiographic parameters (RV E/A and RV AcT/ET) among groups a, b, and c (Table II) . The FEV 1 and %FS were significantly lower in group a than in group c. Patients in group a showed significantly higher heart rate, lower left ventricular E/A, longer DT, and lower plasma norepinephrine concentration than those in groups b and c. There was no significant difference in RV E/A or AcT/ET among the 3 groups. Figure 1 illustrates the representative tracings of transmitral Doppler flow velocities in patients from groups a and b. When heart rate was adjusted to 90 beats/min after isoproterenol infusion, left ventricular E/A and DT were still impaired in group a compared with groups b and c. There was no significant difference in %FS among the 3 groups (Figures 1 and 2) .
Withdrawal of β 2 -AG
The cessation of oral β 2 -AG for 2 weeks significantly improved the left ventricular E/A by 50%, shortened DT by 18%, increased %FS by 6%, and increased the plasma levels of norepinephrine by 64% (Figure 3 and Table   III ). No patients demonstrated acute respiratory failure or impairment in respiratory function.
Discussion
After long-term intake of oral β 2 -AG, patients with bronchial asthma were shown retrospectively and prospectively to have left ventricular diastolic dysfunction. Nonfatal heart failure was more frequently noted in patients with β 2 -AG than in patients without β 2 -AG during the mean follow-up period of 7.7 years. Furthermore, in both prospective and β 2 -AG withdrawal studies, the left ventricular diastolic dysfunction was prominent and reversible in patients with oral β 2 -AG.
Using a prescription-event monitoring technique, Martin et al 7 assessed the safety of bambuterol, a longacting oral β 2 -AG, by comparing the mast-cell-stabilizing drug nedocromil and found that the age-and sexadjusted relative risk ratio of nonfatal cardiac failure in association to bambuterol was 3.41 (P < .0001). The results of the current study are consistent with these large-scale clinical observations. 7 To explain the occurrence of cardiac failure in 3 cohorts without cardiovascular diseases, Martin et al speculated that rather than being cardiotoxic, oral β 2 -AG may worsen or "unmask" previously existing heart failure. In other studies, acute cardiac death was also noted among subjects with 11 ± 1 10 ± 1 9 ± 1 %FS 36 ± 1* 38 ± 1 39 ± 1 LV E/A 0.8 ± 0.1 † 1.5 ± 0.2 1.5 ± 0.1 DT (ms) 220 ± 7 † 182 ± 6 181 ± 6 RV E/A 1.2 ± 0.1 1.6 ± 0. Table II . Baseline data in study 2 potentially lethal conditions. 5 However, the relation between disease severity and cardiac mortality was not conclusive in the current study, particularly because of the small numbers of acute cardiac death. In the examination of medical records (study 1), mean heart rate at rest was significantly higher in patients with β 2 -AG than in patients without β 2 -AG. Such a difference in heart rate modifies the left ventricular systolic and diastolic parameters, especially E/A and DT. 16 Although the heart rate was adjusted to 90 beats/min by isoproterenol infusion in the study 2, the impairment of left ventricular diastolic function was obvious in patients with oral β 2 -AG. The RV E/A or %FS were in similar levels between patients with long-term use of oral β 2 -AG and without β 2 -AG. Such differences in responses to oral β 2 -AG between right and left ventricular relaxation have not yet been documented.
Previous experimental studies clearly showed pulmonary β 2 -adrenoceptor desensitization but not the level of plasma catecholamines. 18 In the current study, decreased concentration of plasma norepinephrine was noted in patients of group a and was reversibly increased toward the normal level after the cessation of β 2 -AG. This suggests the decrease in the intrinsic sympathetic activities in patients with oral β 2 -AG. This may correlate with a downregulation of β-adrenergic receptors in various organ levels. It is also well known that long-term β-adrenoceptor stimulation plays an important role in the relaxation of the left ventricle. 19, 20 Importantly, β 2 -adrenergic receptors have been reported to be downregulated to a greater extent than β 1 -adrenergic receptors in the heart with prolonged in vivo infusion of isoprenaline. 21, 22 The left ventricular diastolic function improved significantly 2 weeks after the cessation of β 2 -AG. This improvement was associated with the significant increase of plasma norepinephrine concentration. Therefore, agonist-induced cardiac dysfunction was reversible. The left ventricular %FS at rest tended to be lower in patients with β 2 -AG than in patients without β 2 -AG. In study 3, the left ventricular %FS increased significantly after the cessation of oral β 2 -AG. Accordingly, long-term use of β 2 -AG may also impair the left ventricular systolic function as well as diastolic function.
Our study had the following limitations. First, numbers of subjects in study 1 were small because the current observational studies have analyzed more than 1000 subjects. However, the present observation cannot be repeated on a large scale because of ethical considerations. The numbers of oral β 2 -AG prescriptions have recently been decreased because of the publicity of the International guidelines. 14 Thus we believe that this study is unique and provides lessons for our future clinical practice. Second, we could not specify the American Heart Journal December 2001
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Figure 1
Representative tracings of transmitral Doppler flow velocities in patient of group a and patient of group b. To match heart rate to 90 beats/min, echocardiographic parameters were measured during intravenous isoproterenol infusion. LV E/A and DT were further deteriorated in group a but were unchanged in group b. ISO, Isoproterenol infusion.
Figure 2
Echocardiographic parameters before and during intravenous isoproterenol infusion. LV E/A and DT in heart rate of 90 beats/min were still impaired in group a compared with groups b and c, whereas there was no significant difference in %FS among 3 groups. ISO, Isoproterenol infusion. All data are shown as mean ± SEM. *P < .05 vs baseline.
mechanisms by which the left ventricular diastolic function is impaired with long-term use of β 2 -AG. Third, the time course of the alteration in left ventricular diastolic function after the start or discontinuation of β 2 -AG remains unexamined. Finally, the causal relation of left ventricular diastolic dysfunction to the occurrence of heart failure in patients with oral β 2 -AG has not been demonstrated.
In conclusion, our study demonstrated that the regular use of oral β 2 -AG induced left ventricular diastolic dysfunction along with the suppression of intrinsic sympathetic activities. Such left ventricular diastolic dysfunction was reversible after 2 weeks' cessation of β 2 -AG. These findings may suggest the importance of a large-scale study to establish the intermittent withdrawal of oral β 2 -AG use world-wide.
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